Continuous quinacrine treatment results in the formation of drug-resistant prions.
Quinacrine is a potent antiprion compound in cell culture models of prion disease but has failed to show efficacy in animal bioassays and human clinical trials. Previous studies demonstrated that quinacrine inefficiently penetrates the blood-brain barrier (BBB), which could contribute to its lack of...
Guardado en:
Autores principales: | Sina Ghaemmaghami, Misol Ahn, Pierre Lessard, Kurt Giles, Giuseppe Legname, Stephen J DeArmond, Stanley B Prusiner |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2009
|
Materias: | |
Acceso en línea: | https://doaj.org/article/fcfbe9ebc1594422855e2fb3b5334f33 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Investigating the conformational stability of prion strains through a kinetic replication model.
por: Mattia Zampieri, et al.
Publicado: (2009) -
Quinacrine-CASIN combination overcomes chemoresistance in human acute lymphoid leukemia
por: Limei Wu, et al.
Publicado: (2021) -
Quinacrine directly dissociates amyloid plaques in the brain of 5XFAD transgenic mouse model of Alzheimer’s disease
por: Sohui Park, et al.
Publicado: (2021) -
Effects of betamethasone, sulindac and quinacrine drugs on the inflammatory neoangiogenesis response induced by polyurethane sponge implanted in mouse
por: ILLANES,JULIO, et al.
Publicado: (2002) -
De novo [PSI +] prion formation involves multiple pathways to form infectious oligomers
por: Jaya Sharma, et al.
Publicado: (2017)